Real-world experience of nintedanib for progressive fibrosing interstitial lung disease in the UK.
Giles DixonSamuel HagueSarah MulhollandHuzaifa AdamaliAye Myat Noe KhinHannah ThouldRoisin ConnonPaul MinnisEoin MurtaghFasihul KhanSameen ToorAlexandra LawrenceMarium NaqviAlex G WestRobina K CokerKatie WardLeda YazbeckSimon Paul HartTheresa GarfootKate NewmanPilar Rivera-OrtegaLachlan StranksPaul BeirneJessica BradleyCatherine RowanSarah AgnewMahin AhmadLisa G SpencerJoshua AigbiriorAhmed FahimAndrew M WilsonElizabeth ButcherSy Giin ChongGauri SainiSabrina ZulfikarFelix ChuaPeter M GeorgeMaria KokosiVasileios KouranosPhilip L MolyneauxElisabetta RenzoniBenedetta VitriAthol U WellsLisa M NicolStephen BianchiRaman KularHuaJian LiuAlexander JohnSarah BarthMelissa WickremasingheIan A ForrestIan GrimesA John SimpsonSophie V FletcherMark G JonesEmma KinsellaJennifer NaftelNicola WoodJodie ChalmersAnjali CrawshawLouise E CrowleyDavinder P S DosanjhChristopher C HuntleyGareth I WaltersTimothy GatheralCatherine PlumShiva BikmallaRaja MuthusamiHelen StoneJonathan Carl Luis RodriguesKrasimira Tsaneva-AtanasovaChris J ScottonMichael A GibbonsShaney Louise BarrattPublished in: ERJ open research (2024)
We have demonstrated the use of nintedanib for the treatment of PF-ILD across a broad range of underlying conditions. Nintedanib is frequently co-prescribed alongside immunosuppressive and immunomodulatory therapy. The use of nintedanib for the treatment of PF-ILD has demonstrated acceptable tolerability in a real-world setting.